NASDAQ:ENDP - Endo International Stock Price, Price Target & More

$5.65 +0.13 (+2.36 %)

(As of 04/24/2018 02:19 PM ET)

Previous Close$5.52

Today's Range$5.53 - $5.73

52-Week Range$5.27 - $14.15

Volume1.54 million shs

Average Volume5.49 million shs

Market Capitalization$1.23 billion

P/E Ratio1.47

Dividend YieldN/A

Beta0.38

About Endo International (NASDAQ:ENDP)

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals. The U.S. Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, abuse-deterrent products, liquids, semi-solids, patches, powders, ophthalmics, sprays, and sterile injectables, as well as products for the pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health, and cardiovascular disease markets. The U.S. Branded Pharmaceuticals segment provides XIAFLEX for the treatment of Dupuytren's contracture and Peyronie's diseases; SUPPRELIN LA for central precocious puberty treatment; TESTOPEL, a long-acting implantable pellet for the treatment of central precocious puberty; NASCOBAL, a nasal spray to treat vitamin B12 deficiency; and AVEED for the treatment of hypogonadism. This segment also offers pain management products, such as PERCOCET, VOLTAREN Gel, and LIDODERM; TESTIM Gel for the treatment of endogenous testosterone; and FORTESTA Gel for hypogonadism treatment. The International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, and oncology. It sells its branded pharmaceuticals and generics directly to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors, as well as through wholesale drug distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.

Receive ENDP News and Ratings via Email

Sign-up to receive the latest news and ratings for ENDP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryPharmaceuticals

SectorMedical

SymbolNASDAQ:ENDP

CUSIP29264F20

Webwww.endo.com

Phone011-353-1268-2000

Debt

Debt-to-Equity Ratio17.00%

Current Ratio1.02%

Quick Ratio0.85%

Price-To-Earnings

Trailing P/E Ratio1.47

Forward P/E Ratio2.42

P/E GrowthN/A

Sales & Book Value

Annual Sales$3.47 billion

Price / Sales0.36

Cash Flow$8.5606 per share

Price / Cash0.66

Book Value$2.17 per share

Price / Book2.60

Profitability

EPS (Most Recent Fiscal Year)$3.84

Net Income$-2,035,430,000.00

Net Margins-58.68%

Return on Equity81.03%

Return on Assets7.02%

Miscellaneous

Employees3,039

Outstanding Shares223,340,000

How to Become a New Pot Stock Millionaire

Endo International (NASDAQ:ENDP) Frequently Asked Questions

What is Endo International's stock symbol?

Endo International trades on the NASDAQ under the ticker symbol "ENDP."

How were Endo International's earnings last quarter?

Endo International plc (NASDAQ:ENDP) released its quarterly earnings results on Tuesday, February, 27th. The company reported $0.77 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.62 by $0.15. The company earned $768.64 million during the quarter, compared to analysts' expectations of $762.29 million. Endo International had a negative net margin of 58.68% and a positive return on equity of 81.03%. The business's quarterly revenue was down 38.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.77 earnings per share. View Endo International's Earnings History.

When is Endo International's next earnings date?

Endo International is scheduled to release their next quarterly earnings announcement on Tuesday, May, 8th 2018. View Earnings Estimates for Endo International.

What guidance has Endo International issued on next quarter's earnings?

Endo International updated its FY18 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of $2.15-2.55 for the period, compared to the Thomson Reuters consensus estimate of $2.86. The company issued revenue guidance of $2.6-2.8 billion, compared to the consensus revenue estimate of $3.03 billion.

What price target have analysts set for ENDP?

20 Wall Street analysts have issued 1-year price objectives for Endo International's shares. Their predictions range from $7.00 to $16.00. On average, they anticipate Endo International's share price to reach $9.4063 in the next year. View Analyst Ratings for Endo International.

What are Wall Street analysts saying about Endo International stock?

Here are some recent quotes from research analysts about Endo International stock:

1. Cantor Fitzgerald analysts commented, "Takeaways from the quarter: 1) Executing well against its stated objectives in U.S. generics, during 4Q17, the U.S. generics segment launched six products and submitted two regulatory filings. In 2017, the U.S. generics segment launched 17 products and ENDP made 12 regulatory submissions. As of 12/31/17, ENDP had ~100 ANDAs (~1/3 FTF/FTM) pending with the FDA. 2) Sterile Injectables is a growing franchise. Sterile Injectables revenue increased 16% YOY. This increase was driven by Adrenalin. 3) Important sterile injectable drugs include Vasostrict and Adrenalin. ENDP reported 2017 Vasostrict sales of $400MM and Adrenalin sales of $77MM. 4) As of 12/31/17, ENDP had $987MM in unrestricted cash, net debt of ~$7.3B and a net leverage ratio of 4.6x. 5) 4Q17 cash provided by operating activities was $132MM, compared to $84MM of net cash provided by operating activities in 2016. 6) Cellulite could be a big opportunity for ENDP. RELEASE-1 And RELEASE-2 Phase 3 trials looking at Xiaflex for the treatment cellulite were initiated. Topline data are expected 1Q19. ENDP plans to submit all the data in 2019. ENDP expects to commercialize the product on its own, but would consider strategic alternatives. 7) ENDP thinks that the generic market seems more stable, but it is still early in 2018." (2/27/2018)
2. According to Zacks Investment Research, "While Endo's Sterile Injectables and Branded Specialty products business units continue to perform well, the decline in generics industry persist thereby impacting the company's top-line. The branded pharmaceuticals business contiinues to be impacted by continued generic competition for established products, product divestitures and ceasing shipments of Opana ER. The business is expected to decline further as the year progresses. Endo withdrew opioid pain medication Opana ER (oxymorphone hydrochloride extended release) from the market following FDA’s request in June. The drug represented 4% of total 2016 revenues. The company divested its non-core assets such as Belbuca and restructured its pain franchise to focus particularly on specialty branded business. Shares have underperformed the indutsry in the past one year." (1/15/2018)
3. Mizuho analysts commented, "We Lower PT to $12 from $14; Buy on Valuation Rating Buy Previous Rating No Change Price (1/02) $8.10 Price Target $12.00 Previous Price Target $14.00 Summary We reiterate our Buy rating but lower our PT to $12 from $14. We think 2018 guidance may prove disappointing, but we continue to view the stock as undervalued." (1/3/2018)

Are investors shorting Endo International?

Endo International saw a increase in short interest during the month of March. As of March 29th, there was short interest totalling 36,160,124 shares, an increase of 10.5% from the March 15th total of 32,726,829 shares. Based on an average daily trading volume, of 5,015,686 shares, the days-to-cover ratio is presently 7.2 days. Approximately 18.1% of the company's shares are sold short.

Who are some of Endo International's key competitors?

Some companies that are related to Endo International include Hutchison China MediTech (HCM), Taro Pharmaceutical Industries (TARO), Loxo Oncology (LOXO), FibroGen (FGEN), GW Pharmaceuticals (GWPH), Advanced Accelerator Application (AAAP), Blueprint Medicines (BPMC), Ligand Pharmaceuticals (LGND), Array BioPharma (ARRY), Tesaro (TSRO), Ultragenyx Pharmaceutical (RARE), Emergent BioSolutions (EBS), Amicus Therapeutics (FOLD), Ascendis Pharma (ASND) and Evotec A.G. (EVTCY).

Who are Endo International's key executives?

Endo International's management team includes the folowing people:

Mr. Paul V. Campanelli, CEO, Pres & Director (Age 56)
Mr. Blaise Coleman, Exec. VP & CFO (Age 44)
Mr. Terrance J. Coughlin, Exec. VP & COO (Age 52)
Mr. Matthew Joseph Maletta, Exec. VP & Chief Legal Officer (Age 46)
Mr. Daniel A. Rudio, Chief Accounting Officer, Sr. VP & Controller

Has Endo International been receiving favorable news coverage?

News coverage about ENDP stock has trended somewhat positive on Tuesday, according to Accern Sentiment. The research group rates the sentiment of press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Endo International earned a news sentiment score of 0.14 on Accern's scale. They also assigned media coverage about the company an impact score of 45.28 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

How do I buy shares of Endo International?

Shares of ENDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Endo International's stock price today?

One share of ENDP stock can currently be purchased for approximately $5.65.

How big of a company is Endo International?

Endo International has a market capitalization of $1.23 billion and generates $3.47 billion in revenue each year. The company earns $-2,035,430,000.00 in net income (profit) each year or $3.84 on an earnings per share basis. Endo International employs 3,039 workers across the globe.

How can I contact Endo International?

Endo International's mailing address is First Floor Minerva House Simmonscourt Road Ballsbridge, Dublin L2, 19355. The company can be reached via phone at 011-353-1268-2000 or via email at [email protected]

MarketBeat Community Rating for Endo International (ENDP)

Community Ranking:		2.6 out of 5 ( )
Outperform Votes:		667 (Vote Outperform)
Underperform Votes:		616 (Vote Underperform)
Total Votes:		1,283

MarketBeat's community ratings are surveys of what our community members think about Endo International and other stocks. Vote "Outperform" if you believe ENDP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENDP will underperform the S&P 500 over the long term. You may vote once every thirty days.

Endo International (NASDAQ:ENDP) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

20 Wall Street analysts have issued ratings and price targets for Endo International in the last 12 months. Their average twelve-month price target is $9.4063, suggesting that the stock has a possible upside of 66.48%. The high price target for ENDP is $16.00 and the low price target for ENDP is $7.00. There are currently 1 sell rating, 16 hold ratings and 3 buy ratings for the stock, resulting in a consensus rating of "Hold."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Hold	Hold	Hold
Consensus Rating Score:	2.10	2.15	2.21	2.15
Ratings Breakdown:	1 Sell Rating(s) 16 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 15 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 13 Hold Rating(s) 5 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 15 Hold Rating(s) 4 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$9.4063	$9.7188	$10.9688	$12.8824
Price Target Upside:	66.48% upside	39.24% upside	35.92% upside	68.62% upside

Endo International (NASDAQ:ENDP) Consensus Price Target History

Price Target History for Endo International (NASDAQ:ENDP)

Endo International (NASDAQ:ENDP) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/4/2018	Mizuho	Downgrade	Buy -> Neutral	$12.00 -> $7.00	High
3/10/2018	Barclays	Set Price Target	Hold	$9.00	Low
3/5/2018	BMO Capital Markets	Lower Price Target	Market Perform -> Market Perform	$10.00 -> $9.00	High
2/28/2018	Gabelli	Downgrade	Buy -> Hold		High
2/27/2018	Oppenheimer	Reiterated Rating	Hold		High
2/27/2018	Canaccord Genuity	Set Price Target	Hold	$7.00	High
2/27/2018	Cantor Fitzgerald	Set Price Target	Hold	$7.00	Low
2/26/2018	JMP Securities	Downgrade	Outperform -> Market Perform		Low
2/14/2018	B. Riley	Initiated Coverage	Buy -> Buy	$10.00	High
1/2/2018	Leerink Swann	Initiated Coverage	Outperform -> Outperform	$12.00	High
12/12/2017	Guggenheim	Initiated Coverage	Neutral -> Neutral	$8.50	Low
11/10/2017	Piper Jaffray	Reiterated Rating	Hold	$7.00	N/A
11/10/2017	Citigroup	Lower Price Target	Neutral	$9.00 -> $7.00	N/A
11/10/2017	Royal Bank of Canada	Lower Price Target	Sector Perform -> Sector Perform	$9.00 -> $8.00	N/A
9/28/2017	Goldman Sachs	Initiated Coverage	Sell -> Sell	$7.00	High
8/10/2017	Morgan Stanley	Lower Price Target	Equal Weight	$12.00 -> $8.00	Low
8/10/2017	Cowen	Reiterated Rating	Hold	$16.00	High
8/9/2017	Deutsche Bank	Set Price Target	Buy	$15.00 -> $13.00	Low
6/14/2017	William Blair	Reiterated Rating	Market Perform		Low
6/9/2017	Stifel Nicolaus	Downgrade	Buy -> Hold	$22.00 -> $15.00	High
1/31/2017	Susquehanna Bancshares	Upgrade	Neutral -> Positive		N/A
1/20/2017	JPMorgan Chase	Downgrade	Overweight -> Neutral	$20.00	N/A
9/29/2016	Northland Securities	Upgrade	Market Perform -> Outperform	$27.00	N/A
8/9/2016	UBS	Reiterated Rating	Buy	$30.00	N/A

(Data available from 4/24/2016 forward)

Endo International (NASDAQ:ENDP) Earnings History and Estimates Chart

Earnings by Quarter for Endo International (NASDAQ:ENDP)

Endo International (NASDAQ:ENDP) Earnings Estimates

2018 EPS Consensus Estimate: $2.38

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	3	$0.54	$0.59	$0.56
Q2 2018	3	$0.59	$0.62	$0.60
Q3 2018	3	$0.56	$0.61	$0.59
Q4 2018	3	$0.60	$0.64	$0.62

Endo International (NASDAQ ENDP) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/8/2018		$0.55					N/A
2/27/2018	Before Market	$0.62	$0.77	$762.29 million	$768.64 million	View	Listen
11/9/2017	Q3	$0.85	$0.91	$794.93 million	$786.90 million	View	N/A
8/8/2017	6/30/2017	$0.74	$0.93	$832.66 million	$875.73 million	View	Listen
5/9/2017	Q1 17	$1.10	$1.23	$1.0235 billion	$1.0380 billion	View	Listen
2/28/2017	Q416	$1.63	$1.77	$1.17 billion	$1.2420 billion	View	Listen
11/8/2016	Q316	$0.81	$1.01	$862.47 million	$894.30 million	View	Listen
8/8/2016	Q216	$0.74	$0.86	$873.50 million	$921.00 million	View	Listen
5/5/2016	Q116	$1.04	$1.08	$960.96 million	$963.54 million	View	Listen
2/29/2016	Q415	$1.27	$1.36	$1.07 billion	$1.07 billion	View	Listen
11/5/2015	Q315	$1.00	$1.02	$736.16 million	$746.00 million	View	Listen
8/10/2015	Q215	$1.02	$1.08	$727.45 million	$735.00 million	View	Listen
5/11/2015	Q115	$1.07	$1.17	$714.42 million	$714.00 million	View	Listen
3/2/2015	Q414	$1.13	$1.16	$780.44 million	$800.00 million	View	Listen
11/5/2014	Q314	$0.99	$1.15	$721.11 million	$764.00 million	View	Listen
7/31/2014	Q214	$0.90	$1.06	$644.60 million	$719.00 million	View	Listen
5/1/2014	Q114	$0.84	$0.92	$608.86 million	$595.00 million	View	Listen
2/28/2014	Q413	$0.93	$0.96	$620.90 million	$584.95 million	View	Listen
11/7/2013	Q313	$1.11	$1.34	$695.63 million	$715.00 million	View	Listen
8/6/2013	Q2 2013	$1.15	$1.42	$721.01 million	$766.51 million	View	Listen
5/7/2013	Q1 2013	$1.08	$1.09	$737.79 million	$709.00 million	View	Listen
2/28/2013	Q4 2012	$1.54	$1.62	$807.98 million	$801.06 million	View	Listen
11/5/2012	Q312	$1.26	$1.28	$788.53 million	$750.50 million	View	N/A
8/7/2012		$1.19	$1.27			View	N/A
5/1/2012		$0.86	$0.87			View	N/A
2/24/2012		$1.32	$1.40			View	N/A
10/27/2011		$1.28	$1.25			View	N/A
8/9/2011		$1.06	$1.05			View	N/A
4/28/2011		$1.00	$1.00			View	N/A
2/28/2011		$0.97	$1.06			View	N/A
11/1/2010	Q3 2010	$0.85	$0.87			View	N/A
7/30/2010	Q2 2010	$0.80	$0.81			View	N/A
4/30/2010	Q1 2010	$0.75	$0.74			View	N/A
2/22/2010	Q4 2009	$0.68	$0.81			View	N/A
10/29/2009	Q3 2009	$0.64	$0.63			View	N/A
7/30/2009	Q2 2009	$0.67	$0.73			View	N/A
4/29/2009	Q1 2009	$0.60	$0.67			View	N/A
2/27/2009	Q4 2008	$0.59	$0.66			View	N/A
10/30/2008	Q3 2008	$0.52	$0.61			View	N/A
7/31/2008	Q2 2008	$0.49	$0.57			View	N/A
4/30/2008	Q1 2008	$0.47	$0.51			View	N/A
2/22/2008	Q4 2007	$0.44	$0.50			View	N/A

(Earnings results data provided by Zacks Investment Research)

Endo International (NASDAQ:ENDP) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Endo International (NASDAQ ENDP) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.50%
Institutional Ownership Percentage: 94.72%

Insider Trading History for Endo International (NASDAQ:ENDP)

Institutional Ownership by Quarter for Endo International (NASDAQ:ENDP)

Endo International (NASDAQ ENDP) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/15/2017	Blaise Coleman	CFO	Buy	6,500	$7.89	$51,285.00	13,729
8/15/2017	Matthew Joseph Maletta	EVP	Buy	3,000	$8.02	$24,060.00	6,984
8/14/2017	Paul Campanelli	CEO	Buy	6,500	$7.71	$50,115.00	213,620
8/10/2017	Terrance J Coughlin	COO	Buy	20,000	$7.70	$154,000.00	181,369
3/16/2017	Paul Campanelli	CEO	Buy	2,300	$10.72	$24,656.00	207,120
3/9/2017	Nancy J. Hutson	Director	Sell	5,325	$10.82	$57,616.50
11/15/2016	Roger H. Kimmel	Director	Sell	14,000	$17.38	$243,320.00
5/11/2016	Arthur J Higgins	Director	Buy	5,000	$13.80	$69,000.00	50,623
5/10/2016	Arthur J Higgins	Director	Buy	11,000	$15.42	$169,620.00	45,623
5/10/2016	Paul Campanelli	Insider	Buy	13,000	$15.53	$201,890.00	201,069
3/17/2016	William Spengler	Director	Buy	1,000	$29.20	$29,200.00	48,835
3/16/2016	William Spengler	Director	Buy	1,000	$35.24	$35,240.00	47,835
3/14/2016	Roger H Kimmel	Director	Buy	1,125	$41.94	$47,182.50	72,237
3/7/2016	Matthew Joseph Maletta	VP	Buy	500	$44.48	$22,240.00	1,000
3/7/2016	Silva Rajiv De	CEO	Buy	2,250	$44.50	$100,125.00	250,705
3/1/2016	Nancy J. Hutson	Director	Sell	3,413	$42.19	$143,994.47	39,990
11/12/2015	Shane Cooke	Director	Buy	4,000	$57.13	$228,520.00	10,179
11/11/2015	Michael Hyatt	Director	Sell	8,000	$55.48	$443,840.00	251,599
11/11/2015	Paul Campanelli	insider	Buy	2,100	$55.69	$116,949.00	15,367
11/11/2015	Silva Rajiv De	CEO	Buy	9,006	$55.52	$500,013.12	13,697
11/11/2015	Suketu Upadhyay	CFO	Buy	4,450	$56.37	$250,846.50	17,740
11/11/2015	Susan Hall	EVP	Buy	1,000	$55.35	$55,350.00	7,515
6/16/2015	Arthur J Higgins	Director	Buy	2,500	$81.10	$202,750.00
4/8/2015	Caroline B Manogue	VP	Sell	105,562	$91.90	$9,701,147.80
11/14/2014	Suketu Upadhyay	CFO	Buy	3,700	$66.94	$247,678.00
8/5/2014	Arthur J Higgins	Director	Buy	3,500	$65.65	$229,775.00
6/9/2014	John Delucca	Director	Sell	6,764	$68.83	$465,566.12
5/29/2014	Caroline B Manogue	VP	Sell	175,033	$72.02	$12,605,876.66
5/1/2014	John Delucca	Director	Sell	8,094	$66.31	$536,713.14	21,596
4/1/2014	John Delucca	Director	Sell	10,384	$68.46	$710,888.64	21,596
3/10/2014	Arthur Higgins	Director	Buy	5,000	$73.00	$365,000.00	5,000
3/10/2014	Ivan Gergel	EVP	Sell	75,637	$72.47	$5,481,413.39	27,649
8/26/2013	Caroline Manogue	VP	Sell	145,592	$39.40	$5,736,324.80	46,422
8/8/2013	Roger Kimmel	Director	Buy	5,478	$36.50	$199,947.00	51,914
4/9/2013	Caroline B Manogue	VP	Sell	35,000	$35.00	$1,225,000.00
11/12/2012	David Holveck	CEO	Buy	7,425	$26.84	$199,287.00

(Data available from 1/1/2013 forward)

Endo International (NASDAQ ENDP) News Headlines

Source:

Date	Headline
	ENDO Arm Gets Health Canada Nod for Treatment www.baystreet.ca - April 23 at 5:18 PM
	Paladin Labs Inc. Announces Launch of New Indication for XIAFLEX® (Collagenase Clostridium Histolyticum), Broadening Its Use to the Treatment of Appropriate Patients with Peyronie's Disease finance.yahoo.com - April 23 at 8:10 AM
	Paladin Labs Announces the Launch of Unisom® Snore Relief, the Only Natural Health Product Throat Spray Available in Canada to Help Relieve Symptoms Associated with Snoring finance.yahoo.com - April 19 at 8:09 AM
	Are Earnings Prospects Improving For Loss-Making Endo International plc’s (NASDAQ:ENDP)? finance.yahoo.com - April 18 at 5:50 PM
	Leerink Swann Analysts Increase Earnings Estimates for Endo International plc (ENDP) www.americanbankingnews.com - April 18 at 8:39 AM
	Endo Receives Paragraph IV Notification on VasostrictÂ www.finanznachrichten.de - April 17 at 6:03 PM
	Endo Receives Paragraph IV Notification on Vasostrict® finance.yahoo.com - April 17 at 6:03 PM
	Endo International (ENDP) Upgraded to "Hold" by BidaskClub www.americanbankingnews.com - April 17 at 3:39 PM
	Leerink Swann Research Analysts Lower Earnings Estimates for Endo International plc (ENDP) www.americanbankingnews.com - April 17 at 6:51 AM
	$689.18 Million in Sales Expected for Endo International plc (ENDP) This Quarter www.americanbankingnews.com - April 16 at 3:43 AM
	Endo International plc (ENDP) Given Average Rating of "Hold" by Brokerages www.americanbankingnews.com - April 15 at 3:34 PM
	Endo International (ENDP) Downgraded by BidaskClub www.americanbankingnews.com - April 14 at 11:26 PM
	$0.54 Earnings Per Share Expected for Endo International plc (ENDP) This Quarter www.americanbankingnews.com - April 14 at 11:17 AM
	Endo to Announce First-Quarter 2018 Financial Results finance.yahoo.com - April 13 at 8:13 AM
	Endo International (ENDP) Stock Rating Lowered by BidaskClub www.americanbankingnews.com - April 12 at 6:46 PM
	Oppenheimer Reaffirms "Hold" Rating for Endo International (ENDP) www.americanbankingnews.com - April 12 at 11:27 AM
	Endo International plc (ENDP) Sees Significant Growth in Short Interest www.americanbankingnews.com - April 12 at 2:18 AM
	Endo International (ENDP) Given a $13.00 Price Target by Deutsche Bank Analysts www.americanbankingnews.com - April 11 at 7:18 PM
	Endo International (ENDP) Given a $9.00 Price Target by Royal Bank of Canada Analysts www.americanbankingnews.com - April 11 at 6:13 PM
	Update: Endo Pharmaceuticals Will Be Crushed By Opioid Litigation seekingalpha.com - April 11 at 5:39 PM
	Endo International (ENDP) Stock Rating Reaffirmed by Mizuho www.americanbankingnews.com - April 11 at 5:01 PM
	New Research: Key Drivers of Growth for Seagate Technology, AveXis, Banco Latinoamericano de Comercio Exterior, S.A, SunOpta, Orix Corp Ads, and Endo International plc — Factors of Influence, Major Initiatives and Sustained Production finance.yahoo.com - April 9 at 8:12 AM
	ValuEngine Upgrades Endo International (ENDP) to "Buy" www.americanbankingnews.com - April 8 at 12:54 PM
	Endo International (ENDP) Rating Lowered to Sell at Zacks Investment Research www.americanbankingnews.com - April 4 at 6:54 PM
	Opioid lawsuits stymie an Endo turnaround, Mizuho says in downgrade finance.yahoo.com - April 4 at 4:20 PM
	Endo International (ENDP) Stock Rating Lowered by Mizuho www.americanbankingnews.com - April 4 at 8:04 AM
	ValuEngine Lowers Endo International (ENDP) to Sell www.americanbankingnews.com - April 3 at 4:16 PM
	What Falling Estimates & Price Mean for Endo International (ENDP) www.zacks.com - April 3 at 8:14 AM
	Endo International (ENDP) Agrees to Extend Temporary Stay of FDA Litigation www.streetinsider.com - April 2 at 5:32 PM
	Endo extends temporary stay of FDA litigation seekingalpha.com - April 2 at 5:32 PM
	Endo Agrees to Extend Temporary Stay of FDA Litigation finance.yahoo.com - April 2 at 8:26 AM
	Endo International (ENDP) Rating Lowered to Hold at ValuEngine www.americanbankingnews.com - March 31 at 2:40 PM
	Endo International (ENDP) Earns Buy Rating from Mizuho www.americanbankingnews.com - March 31 at 12:46 AM
	Zacks: Brokerages Expect Endo International plc - (ENDP) Will Post Quarterly Sales of $689.18 Million www.americanbankingnews.com - March 30 at 2:48 AM
	Arkansas sues opioid manufacturers for roles in epidemic finance.yahoo.com - March 29 at 5:35 PM
	Why Is Endo International (ENDP) Down 15% Since its Last Earnings Report? finance.yahoo.com - March 29 at 5:35 PM
	Cantor Fitzgerald Analysts Give Endo International (ENDP) a $7.00 Price Target www.americanbankingnews.com - March 28 at 7:06 PM
	Endo International plc - (ENDP) Short Interest Up 12.7% in March www.americanbankingnews.com - March 28 at 3:14 AM
	At $5.86, Is Endo International plc (NASDAQ:ENDP) A Buy? finance.yahoo.com - March 26 at 5:25 PM
	Quotidian Technical Highlights on Selected Drug Makers Stocks -- Depomed, DURECT, Endo, and Ionis Pharma www.bizjournals.com - March 26 at 8:15 AM
	See what the IHS Markit Score report has to say about Endo International PLC. finance.yahoo.com - March 26 at 8:15 AM
	FY2018 EPS Estimates for Endo International plc - Cut by Analyst (ENDP) www.americanbankingnews.com - March 26 at 1:27 AM
	Endo International (ENDP) Downgraded to "Hold" at ValuEngine www.americanbankingnews.com - March 25 at 6:25 PM
	Endo International's (ENDP) Hold Rating Reaffirmed at Oppenheimer www.americanbankingnews.com - March 24 at 6:17 PM
	Endo International (ENDP) Raised to Sell at BidaskClub www.americanbankingnews.com - March 24 at 1:56 PM
	Q1 2018 Earnings Forecast for Endo International plc - (ENDP) Issued By B. Riley www.americanbankingnews.com - March 23 at 7:46 AM
	Endo International plc - (ENDP) Given Consensus Recommendation of "Hold" by Brokerages www.americanbankingnews.com - March 21 at 3:55 PM
	Intraday Update: Dow Gains 115 Points Despite Looming Rate Hike finance.yahoo.com - March 20 at 5:23 PM
	Options Traders Expect Huge Moves in Endo International (ENDP) Stock finance.yahoo.com - March 19 at 5:23 PM
	South Dakota sues opioid makers as litigation swells finance.yahoo.com - March 14 at 7:14 PM

Endo International (NASDAQ:ENDP) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Endo International (NASDAQ:ENDP) Income Statement, Balance Sheet and Cash Flow Statement

Endo International (NASDAQ ENDP) Stock Chart for Tuesday, April, 24, 2018

Loading chart…

This page was last updated on 4/24/2018 by MarketBeat.com Staff